Biomarkers


Abstract views: 180 / PDF downloads: 100

Authors

  • Zeliha TUNCER KTO Karatay Üniversitesi

DOI:

https://doi.org/10.5281/zenodo.7926896

Keywords:

Biomarkers, Classification, Validation

Abstract

A biomarker is a property that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. Biomarkers can be DNA, RNA, miRNA, enzyme, nucleic acid, peptides, biomolecules such as hormone or antibody. Biomarkers can be detected in bodily secretions, blood, or excretory products. They can indicate normal or diseased processes in the body. Along with innovative treatment modalities, biomarkers have the potential to change the way medicine is practiced. A cancer biomarker is an indicator of the likelihood of a normal tissue becoming malignant or has become malignant. Cancer biomarkers; they can be nucleic acid, protein or metabolite, or a molecular change, detectable in tissue, blood, urine, or secretions such as nipple aspirates. In this study, it is aimed to share information about biomarkers and their classification.

References

Aronson JK, Ferner RE. Biomarkers-A General Review. Curr Protoc Pharmacol. 2017; 76:9.23.1-9.23.17.

Ajani, J. A., D'Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., Fanta, P., Farjah, F., Gerdes, H., Gibson, M., Glasgow, R. E., Hayman, J. A., Hochwald, S., Hofstetter, W. L., Ilson, D. H., Jaroszewski, D., Johung, K. L., Keswani, R. N., …

Pluchino, L. A. (2019). Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 17(7), 855–883.

El-Deiry, W. S., Goldberg, R. M., Lenz, H. J., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., Kim, E., Brenner, A. J., & Marshall, J. L. (2019). The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA: a cancer journal for clinicians, 69(4), 305–343.

Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dowell, J., Gettinger, S., Gubens, M. A., Hegde, A., Hennon, M., Lackner, R. P., Lanuti, M., Leal, T. A., Lin, J., … Hughes, M. (2021). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network : JNCCN, 19(3), 254–266.

Fuentes-Arderiu X. (2013). What is a biomarker? It's time for a renewed definition. Clinical chemistry and laboratory medicine, 51(9), 1689–1690.

Goossens, N., Nakagawa, S., Sun, X., & Hoshida, Y. (2015). Cancer biomarker discovery and validation. Translational cancer research, 4(3), 256–269.

Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., Pasquier, F., Dubois, B., Tognoni, G., Fiévet, N., Brouwers, N., Bettens, K., Arosio, B., Coto, E., Del Zompo, M., Mateo, I., … Campion, D. (2011). APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular psychiatry, 16(9), 903–907.

Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014). Multitarget stool DNA testing for colorectal-cancer screening. The New England journal of medicine, 370(14), 1287–1297.

Joshi, G., Kaur, R., & Kaur, H. (2016). Biomarkers in cancer.

Jones, P. A., & Laird, P. W. (1999). Cancer epigenetics comes of age. Nature genetics, 21(2), 163–167.

Lassere M. N. (2008). The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Statistical methods in medical research, 17(3), 303–340.

Jiricny J. (1996). Mismatch repair and cancer. Cancer surveys, 28, 47–68.

Moore, H. M., Kelly, A. B., Jewell, S. D., McShane, L. M., Clark, D. P., Greenspan, R., Hayes, D. F., Hainaut, P., Kim, P., Mansfield, E., Potapova, O., Riegman, P., Rubinstein, Y., Seijo, E., Somiari, S., Watson, P., Weier, H. U., Zhu, C., & Vaught, J. (2011). Biospecimen reporting for improved study quality (BRISQ). Journal of proteome research, 10(8), 3429–3438.

Pandey, A., & Mann, M. (2000). Proteomics to study genes and genomes. Nature, 405(6788), 837–846.

Parkinson, D. R., McCormack, R. T., Keating, S. M., Gutman, S. I., Hamilton, S. R., Mansfield, E. A., Piper, M. A., Deverka, P., Frueh, F. W., Jessup, J. M., McShane, L. M., Tunis, S. R., Sigman, C. C., & Kelloff, G. J. (2014). Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 20(6), 1428–1444.

Ralf Huss,Chapter 19 - Biomarkers,Editor(s): Anthony Atala, Julie G. Allickson,Translational Regenerative Medicine,Academic Press,2015,Pages 235-241, ISBN 9780124103962,

Ransohoff D. F. (2007). How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. Journal of clinical epidemiology, 60(12), 1205–1219.

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine, 344(11), 783–792.

Thibodeau, S. N., Bren, G., & Schaid, D. (1993). Microsatellite instability in cancer of the proximal colon. Science (New York, N.Y.), 260(5109), 816–819.

Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., Dillhoff, M., Donahue, T. R., Dotan, E., Ferrone, C. R., Fountzilas, C., Hardacre, J., Hawkins, W. G., Klute, K., Ko, A. H., Kunstman, J. W., … George, G. V. (2021). Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 19(4), 439–457.

Walt D. R. (2000). Techview: molecular biology. Bead-based fiber-optic arrays. Science (New York, N.Y.), 287(5452), 451–452.

Published

2023-05-12

How to Cite

TUNCER, Z. (2023). Biomarkers. GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES, 8(2), 366–370. https://doi.org/10.5281/zenodo.7926896

Issue

Section

Articles